Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 230
Filtrar
Más filtros

Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
Aging (Albany NY) ; 16(7): 6521-6536, 2024 Apr 12.
Artículo en Inglés | MEDLINE | ID: mdl-38613798

RESUMEN

Acute lung injury (ALI) is a major cause of acute respiratory failure with a high morbidity and mortality rate, and effective therapeutic strategies for ALI remain limited. Inflammatory response is considered crucial for the pathogenesis of ALI. Garlic, a globally used cooking spice, reportedly exhibits excellent anti-inflammatory bioactivity. However, protective effects of garlic against ALI have never been reported. This study aimed to investigate the protective effects of garlic oil (GO) supplementation on lipopolysaccharide (LPS)-induced ALI models. Hematoxylin and eosin staining, pathology scores, lung myeloperoxidase (MPO) activity measurement, lung wet/dry (W/D) ratio detection, and bronchoalveolar lavage fluid (BALF) analysis were performed to investigate ALI histopathology. Real-time polymerase chain reaction, western blotting, and enzyme-linked immunosorbent assay were conducted to evaluate the expression levels of inflammatory factors, nuclear factor-κB (NF-κB), NLRP3, pyroptosis-related proteins, and H2S-producing enzymes. GO attenuated LPS-induced pulmonary pathological changes, lung W/D ratio, MPO activity, and inflammatory cytokines in the lungs and BALF. Additionally, GO suppressed LPS-induced NF-κB activation, NLRP3 inflammasome expression, and inflammatory-related pyroptosis. Mechanistically, GO promoted increased H2S production in lung tissues by enhancing the conversion of GO-rich polysulfide compounds or by increasing the expression of H2S-producing enzymes in vivo. Inhibition of endogenous or exogenous H2S production reversed the protective effects of GO on ALI and eliminated the inhibitory effects of GO on NF-κB, NLRP3, and pyroptotic signaling pathways. Overall, these findings indicate that GO has a critical anti-inflammatory effect and protects against LPS-induced ALI by suppressing the NF-κB/NLRP3 signaling pathway via H2S generation.


Asunto(s)
Lesión Pulmonar Aguda , Compuestos Alílicos , Sulfuro de Hidrógeno , Lipopolisacáridos , FN-kappa B , Proteína con Dominio Pirina 3 de la Familia NLR , Piroptosis , Transducción de Señal , Sulfuros , Lesión Pulmonar Aguda/metabolismo , Lesión Pulmonar Aguda/prevención & control , Lesión Pulmonar Aguda/patología , Lesión Pulmonar Aguda/inducido químicamente , Lesión Pulmonar Aguda/tratamiento farmacológico , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Animales , FN-kappa B/metabolismo , Piroptosis/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Compuestos Alílicos/farmacología , Compuestos Alílicos/uso terapéutico , Sulfuros/farmacología , Sulfuros/uso terapéutico , Masculino , Sulfuro de Hidrógeno/metabolismo , Ratones , Pulmón/patología , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Ajo/química , Antiinflamatorios/farmacología , Ratones Endogámicos C57BL , Suplementos Dietéticos
2.
J Ethnopharmacol ; 326: 117778, 2024 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-38310990

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: In China, the Chinese patent drug Realgar-Indigo naturalis Formula (RIF) is utilized for the therapy of acute promyelocytic leukemia (APL). Comprising four traditional Chinese herb-Realgar, Indigo naturalis, Salvia miltiorrhiza, and Pseudostellaria heterophylla-it notably includes tetra-arsenic tetra-sulfide, indirubin, tanshinone IIa, and total saponins of Radix Pseudostellariae as its primary active components. Due to its arsenic content, RIF distinctly contributes to the therapy for APL. However, the challenge of arsenic resistance in APL patients complicates the clinical use of arsenic agents. Interestingly, RIF demonstrates a high remission rate in APL patients, suggesting that its efficacy is not significantly compromised by arsenic resistance. Yet, the current state of research on RIF's ability to reverse arsenic resistance remains unclear. AIM OF THE STUDY: To investigate the mechanism of different combinations of the compound of RIF in reversing arsenic resistance in APL. MATERIALS AND METHODS: The present study utilized the arsenic-resistant HL60-PMLA216V-RARα cell line to investigate the effects of various RIF compounds, namely tetra-arsenic tetra-sulfide (A), indirubin (I), tanshinone IIa (T), and total saponins of Radix Pseudostellariae (S). The assessment of cell viability, observation of cell morphology, and evaluation of cell apoptosis were performed. Furthermore, the mitochondrial membrane potential, changes in the levels of PMLA216V-RARα, apoptosis-related factors, and the PI3K/AKT/mTOR pathway were examined, along with autophagy in all experimental groups. Meanwhile, we observed the changes about autophagy after blocking the PI3K or mTOR pathway. RESULTS: Tanshinone IIa, indirubin and total saponins of Radix Pseudostellariae could enhance the effect of tetra-arsenic tetra-sulfide down-regulating PMLA216V-RARα, and the mechanism was suggested to be related to inhibiting mTOR pathway to activate autophagy. CONCLUSIONS: We illustrated that the synergistic effect of different compound combinations of RIF can regulate autophagy through the mTOR pathway, enhance cell apoptosis, and degrade arsenic-resistant PMLA216V-RARα.


Asunto(s)
Abietanos , Arsénico , Arsenicales , Medicamentos Herbarios Chinos , Leucemia Promielocítica Aguda , Saponinas , Humanos , Arsénico/efectos adversos , Leucemia Promielocítica Aguda/tratamiento farmacológico , Leucemia Promielocítica Aguda/inducido químicamente , Fosfatidilinositol 3-Quinasas , Arsenicales/farmacología , Arsenicales/uso terapéutico , Sulfuros/farmacología , Sulfuros/uso terapéutico , Saponinas/uso terapéutico
3.
Nanomedicine (Lond) ; 18(30): 2185-2204, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-38116732

RESUMEN

Copper sulfide nanoparticles (CuS NPs) have attracted growing interest in biomedical research due to their remarkable properties, such as their high photothermal and thermodynamic capabilities, which are ideal for anticancer and antibacterial applications. This comprehensive review focuses on the current state of antitumor and antibacterial applications of CuS NPs. The initial section provides an overview of the various approaches to synthesizing CuS NPs, highlighting the size, shape and composition of CuS NPs fabricated using different methods. In this review, the mechanisms underlying the antitumor and antibacterial activities of CuS NPs in medical applications are discussed and the clinical challenges associated with the use of CuS NPs are also addressed.


Asunto(s)
Infecciones Bacterianas , Nanopartículas , Neoplasias , Humanos , Cobre/uso terapéutico , Fototerapia , Nanopartículas/uso terapéutico , Neoplasias/tratamiento farmacológico , Sulfuros/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Antibacterianos/uso terapéutico
4.
Invest New Drugs ; 40(6): 1231-1243, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-36287298

RESUMEN

Acute promyelocytic leukemia (APL) is liable to induce disseminated intravascular coagulation and has a high early mortality. Although the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has significantly improved the complete remission rate, there are still some patients developed drug resistance. Growing evidence suggests that natural killer (NK) cell-mediated immunotherapy as a new treatment can help slow the progression of hematological malignancies. Previous studies also indicated that some tumors exhibited excellent responsiveness to NK cells in vitro. However, many clinical trial results showed that the anti-tumor effect of NK cells infusion alone was not ideal, which may be related to the inactivation of infiltrating NK cells caused by strong immunosuppression in tumor microenvironment, but the specific mechanism remains to be further explored. In the present study, we demonstrated that low doses of tetra-arsenic tetra-sulfide (As4S4) not only enhanced the in vitro killing of NK-92MI against ATRA-resistant APL cells, but also strengthened the growth inhibition of xenografted tumors in APL mouse model. Mechanistically, As4S4 altered the expression of natural killer group 2 member D ligands (NKG2DLs) and cytokines in APL cells, and PD-1 in NK-92MI cells. In addition, database retrieval results further revealed the relationship between the differentially regulated molecules of As4S4 and immune infiltration and its impact on prognosis. In conclusion, our findings confirmed the potential of As4S4 as an adjuvant for NK-92MI in the treatment of ATRA-resistant APL.


Asunto(s)
Arsénico , Arsenicales , Leucemia Promielocítica Aguda , Animales , Ratones , Leucemia Promielocítica Aguda/tratamiento farmacológico , Leucemia Promielocítica Aguda/metabolismo , Leucemia Promielocítica Aguda/patología , Arsénico/uso terapéutico , Arsenicales/farmacología , Arsenicales/uso terapéutico , Tretinoina/farmacología , Tretinoina/uso terapéutico , Sulfuros/farmacología , Sulfuros/uso terapéutico , Inmunoterapia , Óxidos/farmacología , Óxidos/uso terapéutico , Microambiente Tumoral
5.
ACS Nano ; 16(9): 14860-14873, 2022 09 27.
Artículo en Inglés | MEDLINE | ID: mdl-36094899

RESUMEN

Owing to its flexibility and high treatment efficiency, phototherapy is rapidly emerging for treating bacteria-induced diseases, but how to improve the sensitivity of bacteria to reactive oxygen species (ROS) and heat simultaneously to kill bacteria under mild conditions is still a challenge. Herein, we designed a NIR light catalyst (Bi2S3-S-nitrosothiol-acetylcholine (BSNA)) by transforming •O2- into peroxynitrite in situ, which can enhance the bacterial sensibility to ROS and heat and kill bacteria under a mild temperature. The transformed peroxynitrite in situ possessed a stronger ability to penetrate cell membranes and antioxidant capacity. The BSNA nanoparticles (NPs) inhibited the bacterial glucose metabolic process through down-regulated xerC/xerD expression and disrupted the HSP70/HSP90 secondary structure through nitrifying TYR179. Additionally, the synergistic effect of the designed BSNA and clinical antibiotics increased the antibacterial activity. In the case of tetracycline-class antibiotics, BSNA NPs induced phenolic hydroxyl group structure changes and inhibited the interaction between tetracycline and targeted t-RNA recombinant protein. Besides, BSNA stimulated production of more CD8+ T cells and reduced common complications in peritonitis, which provided immunotherapy activity. The targeted and anti-infective effect of BSNA suggested that we propose a nanotherapeutic strategy to achieve more efficient synergistic therapy under mild temperatures.


Asunto(s)
Infecciones Bacterianas , Nanopartículas , S-Nitrosotioles , Acetilcolina , Antibacterianos/química , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antioxidantes , Bacterias/metabolismo , Infecciones Bacterianas/tratamiento farmacológico , Bismuto , Linfocitos T CD8-positivos , Glucosa , Humanos , Inmunoterapia , Nanopartículas/química , Ácido Peroxinitroso , Fototerapia , ARN , Especies Reactivas de Oxígeno/metabolismo , Proteínas Recombinantes , Sulfuros/química , Sulfuros/farmacología , Sulfuros/uso terapéutico , Tetraciclinas
6.
Acta Trop ; 235: 106580, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35908577

RESUMEN

Hymenolepis nana, a parasitic tapeworm distributed worldwide, is very prevalent in countries with poor sanitary conditions. Garlic is widely used as a seasoning and medicinal plant all over the world, and its derivatives have proven anti-microbial and anti-inflammatory effects. Our study explored the cestocidal and therapeutic effects of allicin derivatives against H. nana in vitro and in vivo. Worms taken from a host were cultured in vitro, and the effects of allyl sulfide (DAS), allyl disulfide (DADS) and dimethyl sulfoxide (DMSO) treatments were observed. Male BALB/c mice were then fed eggs to produce infection, given drugs for ten days and dissected. The results of this study showed that DADS in garlic exhibited good cestocidal effects in vitro and in vivo. DADS and DATS reduced motility, induced mortality and damaged body segments of worms in vitro. In vivo, the number of worms in the low-dose and high-dose DADS groups was significantly less than the infected control group. DADS effected cytokine changes in BALB/c mice after infection. IFN-γ increased, IL-2, 4, 6 and 13 decreased, and IL-5, 10 and IL-12 p70 did not change significantly. As a medicinal plant, garlic has many active ingredients that can developed as anti-microbial or parasite-related drugs.


Asunto(s)
Compuestos Alílicos , Ajo , Hymenolepis nana , Compuestos Alílicos/farmacología , Compuestos Alílicos/uso terapéutico , Animales , Antioxidantes , Citocinas , Ratones , Ratones Endogámicos BALB C , Sulfuros/farmacología , Sulfuros/uso terapéutico
7.
Gene ; 816: 146172, 2022 Mar 30.
Artículo en Inglés | MEDLINE | ID: mdl-34995734

RESUMEN

OBJECTIVE: Synovial sarcoma (SS) is a malignant soft tissue sarcoma and its natural history is a long, indolent clinical course followed by high rate of local recurrence and distant metastasis. Current therapies are still limited in increasing satisfactory of 5-year survival, especially for patients with recurrence and metastasis. Accordingly, finding new therapeutic drug for SS treatment is clinically urgent need. Diallyl trisulfide (DATS), a bioactive compound derived from garlic, is reported as a promising anti-cancer agent for various carcinomas. However, its effect on anti-SS remains unknown. This study investigated the anti-SS effect of DATS in human synovial sarcoma SW982 cells. METHODS: CCK-8 assay were used to examine the cell viability. High-content Imaging System was used to examine the apoptosis, intracellular ROS and autophagy. Flow cytometry was used to detect cell cycle. qPCR and Western blot were used to examine the expression of related mRNA and protein. High-throughput RNA-sequencing and bio-information analysis were used to investigate the mRNA profiling. RESULTS: The results showed a suppressive effect of DATS on tumor biology of SW982 cells including inducing apoptosis, triggering G2/M cell cycle arrest, elevating intracellular ROS and damaging mitochondria. Further high-throughput RNA-sequencing analysis clarified a comprehensive molecular portrait for DATS-induced transcriptional regulation. Besides, protein-protein interaction (PPI) analysis demonstrated that a network consisted of FOXM1, CCNA2, CCNB1, MYBL2, PLK1 and CDK1 might be response for DATS-induced G2/M cell cycle arrest and increased intracellular ROS. Notably, protein feature analysis revealed structure enrichment in microtubule network like kinesin motors domain, and tubulin domain. Molecular function analysis suggested that DATS-induced dysfunction of microtubule network might be the major cause for its effect on cell cycle arrest and successive apoptosis. Furthermore, 28 hub genes (including KIF2C, PLK1, CDK1, BIRC5, CCNB2, CENPF, TPX2, TOP2A and so on) were determined. Finally, pathway analysis showed that DATS-induced differentially expressed genes were mainly involved in cell cycle. CONCLUSION: Collectively, our findings for the first time provided the DATS-induced cellular response and transcriptional profiling of SW982 cells, which proposes that suppression of DATS on SS is multi-targeted and represent a therapeutic evidence for SS.


Asunto(s)
Compuestos Alílicos/uso terapéutico , Antineoplásicos Fitogénicos/uso terapéutico , Sarcoma Sinovial/tratamiento farmacológico , Sulfuros/uso terapéutico , Autofagia/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Bases de Datos Genéticas , Ensayos de Selección de Medicamentos Antitumorales , Citometría de Flujo , Ajo/química , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Mitocondrias/efectos de los fármacos , Mapas de Interacción de Proteínas/efectos de los fármacos , ARN Mensajero , ARN Neoplásico/química , Especies Reactivas de Oxígeno/metabolismo , Sarcoma Sinovial/genética , Análisis de Secuencia de ARN , Transcriptoma
8.
Nutr Health ; 28(2): 207-212, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-34044656

RESUMEN

BACKGROUND: Therapy resistance is the underlying reason for poor outcome in prostate cancer (PCa) patients. Diallyl trisulfide (DATS) is an organosulfur compound present in garlic. DATS has been shown to target PCa cells by induction of apoptosis, increase in the production of reactive oxygen species, degradation of ferritin protein and increase in the labile iron (Fe) pool. AIM: We hypothesize that DATS could induce ferroptosis, an Fe-dependent, unique non-apoptotic form of regulated cell death to eliminate therapy resistance encountered by PCa patients. METHODS: In vitro and in vivo studies should be performed to test the hypothesis. RESULTS: As per the hypothesis, DATS would eliminate apoptotic resistance via inducing ferroptosis. CONCLUSION: Since apoptosis resistance has been reported to be the underlying mechanism of therapy resistance in PCa, DATS could be used to effectively target PCa cells by overcoming apoptosis resistance and inducing ferroptosis-mediated cell death of PCa cells.


Asunto(s)
Compuestos Alílicos , Ferroptosis , Ajo , Neoplasias de la Próstata , Compuestos Alílicos/farmacología , Compuestos Alílicos/uso terapéutico , Antioxidantes , Humanos , Masculino , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/metabolismo , Sulfuros/farmacología , Sulfuros/uso terapéutico
9.
PLoS One ; 16(9): e0257396, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34550981

RESUMEN

Leukotrienes play a central pathophysiological role in both paediatric and adult asthma. However, 35% to 78% of asthmatics do not respond to leukotriene inhibitors. In this study we tested the role of the LTA4H regulatory variant rs2660845 and age of asthma onset in response to montelukast in ethnically diverse populations. We identified and genotyped 3,594 asthma patients treated with montelukast (2,514 late-onset and 1,080 early-onset) from seven cohorts (UKBiobank, GoSHARE, BREATHE, Tayside RCT, PAGES, GALA II and SAGE). Individuals under montelukast treatment experiencing at least one exacerbation in a 12-month period were compared against individuals with no exacerbation, using logistic regression for each cohort and meta-analysis. While no significant association was found with European late-onset subjects, a meta-analysis of 523 early-onset individuals from European ancestry demonstrated the odds of experiencing asthma exacerbations by carriers of at least one G allele, despite montelukast treatment, were increased (odds-ratio = 2.92, 95%confidence interval (CI): 1.04-8.18, I2 = 62%, p = 0.0412) compared to those in the AA group. When meta-analysing with other ethnic groups, no significant increased risk of asthma exacerbations was found (OR = 1.60, 95% CI: 0.61-4.19, I2 = 85%, p = 0.342). Our study demonstrates that genetic variation in LTA4H, together with timing of asthma onset, may contribute to variability in montelukast response. European individuals with early-onset (≤18y) carrying at least one copy of rs2660845 have increased odd of exacerbation under montelukast treatment, presumably due to the up-regulation of LTA4H activity. These findings support a precision medicine approach for the treatment of asthma with montelukast.


Asunto(s)
Acetatos/uso terapéutico , Asma/tratamiento farmacológico , Ciclopropanos/uso terapéutico , Epóxido Hidrolasas/genética , Farmacogenética , Quinolinas/uso terapéutico , Sulfuros/uso terapéutico , Adolescente , Adulto , Edad de Inicio , Alelos , Antiasmáticos/uso terapéutico , Asma/fisiopatología , Niño , Preescolar , Estudios Transversales , Europa (Continente) , Femenino , Genotipo , Hospitalización , Humanos , Antagonistas de Leucotrieno/uso terapéutico , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Análisis de Regresión , Riesgo , Adulto Joven
10.
Food Chem Toxicol ; 157: 112581, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34562529

RESUMEN

Lung cancer caused one-quarter of all cancer deaths that was more than other cancers. Chemoprevention is a potential strategy to reducing lung cancer incidence and death, and the effective chemopreventive agents are needed. We investigated the efficacy and mechanism of garlic oil (GO), the garlic product, in the chemoprevention of tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung cancer in A/J mice and MRC-5 cell models in the present study. As a result, it was demonstrated that GO significantly inhibited the NNK-induced lung cancer in vivo and protected MRC-5 cells from NNK-induced cell damage. GO could induce the expressions of the phase II drug-metabolizing enzymes, including NAD(P)H: quinone oxidoreductase 1 (NQO-1), glutathione S-transferase alpha 1 (GSTA1), and antioxidative enzymes heme oxygenase-1 (HO-1). These results supported the potential of GO as a novel candidate agent for the chemoprevention of tobacco carcinogens induced lung cancer.


Asunto(s)
Compuestos Alílicos/uso terapéutico , Carcinogénesis/efectos de los fármacos , Neoplasias Pulmonares/prevención & control , Nitrosaminas/toxicidad , Sulfuros/uso terapéutico , Compuestos Alílicos/farmacología , Animales , Benzotiazoles/metabolismo , Western Blotting , Ensayo Cometa , Femenino , Citometría de Flujo , Neoplasias Pulmonares/inducido químicamente , Masculino , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones , Nitrosaminas/antagonistas & inhibidores , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Sulfuros/farmacología
11.
Biomed Pharmacother ; 138: 111316, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33684689

RESUMEN

BACKGROUND: Cardiovascular diseases are the leading cause of death globally, and they are causing enormous socio-economic burden to the developed and developing countries. Allyl Methyl Sulfide (AMS) is a novel cardioprotective metabolite identified in the serum of rats after raw garlic administration. The present study explored the cardioprotective effect of AMS on thoracic aortic constriction (TAC)-induced cardiac hypertrophy and heart failure model in rats. METHODS: Thoracic aortic constriction (TAC) by titanium ligating clips resulted in the development of pressure overload-induced cardiac hypertrophy and heart failure model. Four weeks prior to TAC and for 8 weeks after TAC, Sprague Dawley (SD) rats were administered with AMS (25 and 50 mg/kg/day) or Enalapril (10 mg/kg/day). RESULTS: We have observed AMS (25 and 50 mg/kg/day) intervention significantly improved structural and functional parameters of the heart. mRNA expression of fetal genes i.e., atrial natriuretic peptide (ANP), alpha skeletal actin (α-SA) and beta myosin heavy chain (ß-MHC) were reduced in AMS treated TAC hearts along with decrease in perivascular and interstitial fibrosis. AMS attenuated lipid peroxidation and improved protein expression of endogenous antioxidant enzymes i.e., catalase and manganese superoxide dismutase (MnSOD) along with electron transport chain (ETC) complex activity. AMS increased mitochondrial fusion proteins i.e., mitofusin 1 (MFN1), mitofusin 2 (MFN2) and optic atrophy protein (OPA1), and reduced fission protein i.e., dynamin-related protein 1 (DRP1). Preliminary study suggests that AMS intervention upregulated genes involved in mitochondrial bioenergetics in normal rats. Further, in-vitro studies suggest that AMS reduced mitochondrial reactive oxygen species (ROS), preserved mitochondrial membrane potential and oxygen consumption rate (OCR) in isoproterenol-treated cardiomyoblast. CONCLUSION: This study demonstrated that AMS protected cardiac remodelling, LV dysfunction and fibrosis in pressure overload-induced cardiac hypertrophy and heart failure model by improving endogenous antioxidants and mitochondrial function.


Asunto(s)
Compuestos Alílicos/uso terapéutico , Cardiotónicos/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Mitocondrias Cardíacas/efectos de los fármacos , Sulfuros/uso terapéutico , Compuestos Alílicos/farmacología , Animales , Aorta Torácica/diagnóstico por imagen , Aorta Torácica/efectos de los fármacos , Aorta Torácica/fisiopatología , Cardiomegalia/diagnóstico por imagen , Cardiomegalia/tratamiento farmacológico , Cardiomegalia/fisiopatología , Cardiotónicos/farmacología , Línea Celular , Insuficiencia Cardíaca/diagnóstico por imagen , Insuficiencia Cardíaca/fisiopatología , Masculino , Mitocondrias Cardíacas/fisiología , Ratas , Ratas Sprague-Dawley , Volumen Sistólico/efectos de los fármacos , Volumen Sistólico/fisiología , Sulfuros/farmacología
12.
J Diabetes Res ; 2021: 6404438, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-35127948

RESUMEN

BACKGROUND: Diabetes mellitus (DM) is a chronic metabolic disorder associated with higher risk of having cardiovascular disease. Platelets play a promising role in the pathogenesis of cardiovascular complications in diabetes. Since last several decades, garlic and its bioactive components are extensively studied in diabetes and its complications. Our aim was to explore the antiplatelet property of allyl methyl sulfide (AMS) focusing on ameliorating platelet activation in diabetes. METHOD: We used streptozotocin- (STZ-) induced diabetic rats as model for type 1 diabetes. We have evaluated the effect of allyl methyl sulfide on platelet activation by administrating AMS to diabetic rats for 10 weeks. Flow cytometry-based analysis was used to evaluate the platelet activation, platelet aggregation, platelet macrophage interaction, and endogenous ROS generation in the platelets obtained from control, diabetes, and AMS- and aspirin-treated diabetic rats. RESULTS: AMS treatment for 10 weeks effectively reduced the blood glucose levels in diabetic rats. Three weeks of AMS (50 mg/kg/day) treatment did not reduce the activation of platelets but a significant (p < 0.05) decrease was observed after 10 weeks of treatment. Oral administration of AMS significantly (p < 0.05) reduced the baseline and also reduced ADP-induced aggregation of platelets after 3 and 10 weeks of treatment. Furthermore, 10 weeks of AMS treatment in diabetic rats attenuated the endogenous ROS content (p < 0.05) of platelets and platelet macrophage interactions. The inhibition of platelet activation in diabetic rats after AMS treatment was comparable with aspirin treatment (30 mg/kg/day). CONCLUSION: We observed an inhibitory effect of allyl methyl sulfide on platelet aggregation, platelet activation, platelet macrophage interaction, and increased ROS levels in type 1 diabetes. Our data suggests that AMS can be useful to control cardiovascular complication in diabetes via inhibition of platelet activation.


Asunto(s)
Compuestos Alílicos/farmacología , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Activación Plaquetaria/efectos de los fármacos , Sulfuros/farmacología , Compuestos Alílicos/metabolismo , Compuestos Alílicos/uso terapéutico , Análisis de Varianza , Animales , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/fisiopatología , Modelos Animales de Enfermedad , Citometría de Flujo/métodos , Citometría de Flujo/estadística & datos numéricos , Ajo/metabolismo , Activación Plaquetaria/fisiología , Ratas , Sulfuros/metabolismo , Sulfuros/uso terapéutico
13.
J Ethnopharmacol ; 268: 113559, 2021 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-33159994

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Realgar has been used in traditional remedies for a long history in China and India. It is clinically used to treat diverse cancers, especially acute promyelocytic leukemia (APL), chronic myelogenous leukemia (CML) in China. However, paradoxic roles of realgar to increase or decrease immunity are reported. It is urgent to address this question, due to immune depression can be strongly benefit to cancer development, but detrimental to patients. AIM OF THE STUDY: This present work is to explore whether realgar promote or suppress immune responses, and shed light on its mode of action. Our results should provide cues for rational strategy to explore realgar for clinical use. MATERIAL AND METHODS: Infection model in vivo was established by using Enterococcus faecalis to attack Caenorhabditis elegans, then realgar was used to treat the infected worms to investigate its effects on infectivity and the underlying mechanism. Killing analysis was carried out to test whether realgar can mitigate worm infection. Thermotolerance resistance analysis was used to evaluate if realgar functions hormetic effect. Quantification of live E. faecalis in nematode intestine was employed to ascertain if realgar alleviate the bacterial load in worm gut. Quantitative real-time PCR (qRT-PCR) was used to test the expression of antibacterial effectors. Western blot was used to test the effect of realgar on the expressions of p38 and phospho-p38 in worms infected by E. faecalis. RESULTS: Realgar alleviated the infected worms in strains of N2, glp-4, and daf-2, but failed in sek-1, glp-4; sek-1, and daf-2; daf-16 when p38 MAPK or daf-16 was blocked or inactivated. Western blot assay demonstrated that realgar increased the expression of phosph-p38. Thermotolerance assay showed that realgar played a hormetic role on nemtodes, triggered protective response and reduced bacterial load after realgar treatment for 120 h qRT-PCR demonstrated that realgar significantly increased antibacterial effectors, thus leading to pathogen elimination. CONCLUSION: Realgar increased defenses against E. faecalis in C. elegans by inducing both immune responses and protective responses. It was regulated by p38 MAPK pathway and DAF-16.


Asunto(s)
Arsenicales/uso terapéutico , Enterococcus faecalis/efectos de los fármacos , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Sulfuros/uso terapéutico , Animales , Animales Modificados Genéticamente , Arsenicales/farmacología , Caenorhabditis elegans , Enterococcus faecalis/enzimología , Enterococcus faecalis/inmunología , Infecciones por Bacterias Grampositivas/enzimología , Infecciones por Bacterias Grampositivas/inmunología , Sulfuros/farmacología , Proteínas Quinasas p38 Activadas por Mitógenos/antagonistas & inhibidores , Proteínas Quinasas p38 Activadas por Mitógenos/inmunología , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
14.
Rev. bras. parasitol. vet ; 30(1): e015920, 2021. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1156210

RESUMEN

Abstract The consumption of inadequately thermally treated fish is a public health risk due to the possible propagation of Anisakis larvae. The present study demonstrated the physiological and histopathological changes that accompanied an oral inoculation of crude extracts from fresh and thermally treated Anisakis Type II (L3) in rats. Worms were isolated from a marine fish and examined and identified using light and scanning electron microscopy. The study was performed in 6 rat groups: control (I), garlic oil (GO) inoculated (II), fresh L3 inoculated (III), thermally treated L3 inoculated (IV), fresh L3 + GO inoculated (V), and a thermally treated L3 + GO inoculated (VI) groups. Rats inoculated with fresh and thermally treated L3 showed abnormal liver and kidney functions associated with the destruction of normal architecture. GO produced a protective effect in rat groups inoculated with L3 extracts + GO via the amelioration of liver and kidney functions, which was confirmed by the marked normal structure on histology. Cooking of L3-infected fish induced severe alterations compared to uncooked fish. The administration of garlic before and after fish eating is recommended to avoid the dangerous effect of anisakids, even if they are cooked.


Resumo O consumo de peixe inadequadamente tratado termicamente representa um risco para a saúde pública, com a possibilidade da propagação de larvas de Anisakis. O presente estudo demonstrou as alterações fisiológicas e histopatológicas acompanhadas de inoculação oral de extractos brutos de Anisakis tipo II (L3) frescos e termicamente tratados em ratos. Os vermes foram isolados de um peixe marinho, examinados e identificados por microscopia de luz e eletrônica de varredura. O estudo foi conduzido em 6 grupos de ratos: controle (I), óleo de alho (GO) inoculado (II), L3 fresco inoculado (III), L3 tratado termicamente inoculado (IV), L3 fresco + GO inoculado (V), e um grupo L3 + GO tratado termicamente inoculado (VI). Observou-se que ratos inoculados com L3 fresco e tratados termicamente mostraram funções hepáticas e renais anormais, associadas à destruição da sua arquitetura normal. GO produziu um efeito protector em grupos de ratos inoculados com extractos L3 + GO através da melhoria das funções do fígado e dos rins, o que foi confirmado pela estrutura normal marcada da sua histologia. A cozedura de peixes infectados com L3 induziu alterações mais graves do que os peixes não cozidos. Recomenda-se a administração de alho antes e depois do consumo de peixe, para evitar o efeito perigoso dos anisakids, mesmo que sejam cozidos.


Asunto(s)
Animales , Ratas , Sulfuros/farmacología , Anisakis/efectos de los fármacos , Anisakiasis/prevención & control , Anisakiasis/tratamiento farmacológico , Compuestos Alílicos/uso terapéutico , Compuestos Alílicos/farmacología , Sulfuros/uso terapéutico , Parasitología de Alimentos , Ratas Wistar , Culinaria , Peces/parasitología , Larva , Antihelmínticos/uso terapéutico , Antihelmínticos/farmacología
15.
Int J Mol Sci ; 21(23)2020 Nov 30.
Artículo en Inglés | MEDLINE | ID: mdl-33265949

RESUMEN

This study aimed to examine the effects of diallyl trisulfide (DATS), the most potent polysulfide derived from garlic, on metabolic syndrome and myocardial function in rats with metabolic syndrome (MetS). For that purpose, we used 36 male Wistar albino rats divided into control rats, rats with MetS and MetS rats treated with 40 mg/kg of DATS every second day for 3 weeks. In the first part, we studied the impact of DATS on MetS control and found that DATS significantly raised H2S, decreased homocysteine and glucose levels and enhanced lipid and antioxidative, while reducing prooxidative parameters. Additionally, this polysulfide improved cardiac function. In the second part, we investigated the impact of DATS on ex vivo induced ischemia/reperfusion (I/R) heart injury and found that DATS consumption significantly improved cardiodynamic parameters and prevented oxidative and histo-architectural variation in the heart. In addition, DATS significantly increased relative gene expression of eNOS, SOD-1 and -2, Bcl-2 and decreased relative gene expression of NF-κB, IL-17A, Bax, and caspases-3 and -9. Taken together, the data show that DATS can effectively mitigate MetS and have protective effects against ex vivo induced myocardial I/R injury in MetS rat.


Asunto(s)
Compuestos Alílicos/uso terapéutico , Cardiotónicos/uso terapéutico , Ajo/química , Síndrome Metabólico/tratamiento farmacológico , Sulfuros/uso terapéutico , Compuestos Alílicos/farmacología , Animales , Glucemia/metabolismo , Cardiotónicos/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Prueba de Tolerancia a la Glucosa , Pruebas de Función Cardíaca/efectos de los fármacos , Insulina/sangre , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/patología , Síndrome Metabólico/sangre , Síndrome Metabólico/fisiopatología , Miocardio/patología , Oxidación-Reducción , Estrés Oxidativo/efectos de los fármacos , Ratas Wistar , Sulfuros/farmacología
16.
Drugs ; 80(17): 1831-1851, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32915441

RESUMEN

BACKGROUND: In treating allergic rhinitis, montelukast has the potential to be used as an alternative or addition to an oral antihistamine or intranasal corticosteroid. OBJECTIVE: The objective of this systematic review was to assess the effectiveness of montelukast in treating allergic rhinitis. METHODS: An electronic literature search was performed using the Cochrane Central Register of Controlled Trials, EMBASE, and MEDLINE from 1966 to 21 January 2019. The eligibility criteria were randomized controlled trials comparing montelukast with placebo or other standard treatments. The primary outcomes assessed were daytime nasal symptom score (DNS) and night-time nasal symptom score (NNS). The secondary outcomes assessed were composite nasal symptom score (CSS), daytime eyes symptom score (DES), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ). The meta-analysis was conducted using Review Manager 5.3 software based on the random-effects model. RESULTS: Fifteen studies of 10387 participants met the inclusion criteria. Montelukast was more effective than placebo in improving DNS (mean difference [MD] - 0.12, 95% confidence interval [CI] - 0.15 to - 0.08; p < 0.001), NNS (MD - 0.09, 95% CI - 0.13 to - 0.05; p < 0.001), CSS (MD - 0.08, 95% CI - 0.11 to - 0.06; p < 0.001), DES (MD - 0.17, 95% CI - 0.33 to - 0.02; p < 0.030), and RQLQ (MD - 0.34, 95% CI - 0.49 to - 0.20; p < 0.001). Oral antihistamine was superior to montelukast in improving DNS (MD 0.08, 95% CI 0.03-0.13; p = 0.002), CSS (MD 0.03, 95% CI - 0.02 to 0.07; p = 0.27), DES (MD 0.06, 95% CI 0-0.12; p = 0.040), and RQLQ (MD 0.03, 95% CI - 0.05 to 0.12; p = 0.430). Montelukast was superior to oral antihistamine in improving NNS (MD -0.03, 95% CI - 0.08 to 0.03; p = 0.330). Intranasal fluticasone spray was superior to montelukast in improving DNS (MD 0.71, 95% CI 0.44-0.99; p < 0.001) and NNS (MD 0.63, 95% CI 0.29-0.97; p < 0.001). Combined montelukast and oral antihistamine was superior to oral antihistamine in improving DNS (MD - 0.15, 95% CI - 0.27 to - 0.03; p = 0.010), NNS (MD - 0.16, 95% CI - 0.28 to - 0.05; p = 0.006), CSS (MD - 0.12, 95% CI - 0.25 to - 0.01; p = 0.070), DES (MD - 0.12, 95% CI - 0.30 to 0.06; p = 0.180), and RQLQ (MD - 0.10, 95% CI - 0.28 to 0.08; p = 0.290). Combined montelukast and OAH was superior to montelukast in improving DNS (MD 0.15, 95% CI 0.08-0.21; p < 0.001), NNS (MD 0.05, 95% CI - 0.09 to 0.19; p = 0.510), CSS (MD 0.1, 95% CI 0.03-0.17; p = 0.007), DES (MD 0.18, 95% CI 0-0.36; p = 0.050), and RQLQ (MD 0.07 95% CI - 0.15 to 0.29; p = 0.530). CONCLUSIONS: Montelukast is more effective than placebo in treating the overall symptoms of allergic rhinitis while the combined therapy of montelukast and an oral antihistamine is superior to either montelukast or an oral antihistamine alone.


Asunto(s)
Acetatos/uso terapéutico , Ciclopropanos/uso terapéutico , Antagonistas de Leucotrieno/uso terapéutico , Quinolinas/uso terapéutico , Rinitis Alérgica/tratamiento farmacológico , Sulfuros/uso terapéutico , Administración Intranasal , Administración Oral , Corticoesteroides/administración & dosificación , Quimioterapia Combinada/métodos , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Humanos , Fotoperiodo , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Rinitis Alérgica/diagnóstico , Rinitis Alérgica/psicología , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
17.
Chin J Integr Med ; 26(11): 845-852, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32870478

RESUMEN

OBJECTIVE: To evaluate the efficacy of Chinese medicine acupoint application (CMAA) combined with Western medicine for perennial allergic rhinitis (PAR) in children. METHODS: In this prospective, parallel, randomized, placebo-controlled and single-blind trial from August to September, 2017, 180 children with PAR were randomly assigned to an integrative group (CMAA and Montelukast), CMAA group (CMAA and placebo tablet), or Montelukast group (placebo CMAA and Montelukast). Participants were applied with CMAA for 6 sessions over 2 weeks, and/or Montelukast Chewable Tablet orally once daily for 12 weeks. The changes in severity of symptoms were measured by Visual Analog Scale (VAS) and rhinitis control assessment test (RCAT) at 0, 2, 4 and 12 weeks of treatment. Blood samples were collected for serum interleukin-4, interferon gamma γ and T helper type 1 (Th1)/Th2 flow cytometric analysis at the time points of 0, 4 and 12 weeks. RESULTS: Eight cases dropped out from the trial, 3 in the integrative group, 2 in the CMAA group and 3 in the Montelukast group. The VAS scores decreased significantly while the RCAT scores increased significantly in all three groups at 4 and 12 weeks compared with baseline (P<0.01 or P<0.05). The VAS scores were significantly lower while the RCAT scores were significantly higher in the integrative and CMAA groups than the Montelukast group at 2 and 4 weeks (P<0.01 or P<0.05). At 2, 4 and 12 weeks, the scores of nasal congestion, sneezing, sleep problem, and rhinitis symptom control in the integrative and CMAA groups increased significantly compared with baseline (P<0.01 or P<0.05). The least percentages of Th2 and the most alleviated Th2 shift (highest Th1/Th2) were observed in the integrative group at 12 weeks compared with the other two groups (P<0.05). CONCLUSION: The combination of CMAA with Montelukast might be more effective and appropriate than either option alone for children with PAR. (Registered at Chinese Clinical Trial Register, registration No. ChiCTR-IOR-17012434).


Asunto(s)
Acetatos/uso terapéutico , Puntos de Acupuntura , Ciclopropanos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Quinolinas/uso terapéutico , Rinitis Alérgica Perenne/tratamiento farmacológico , Sulfuros/uso terapéutico , Administración Tópica , Niño , Preescolar , Quimioterapia Combinada , Femenino , Humanos , Masculino , Estudios Prospectivos , Método Simple Ciego
18.
Oxid Med Cell Longev ; 2020: 7856318, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32617142

RESUMEN

Allylmethylsulfide (AMS) is a novel sulfur metabolite found in the garlic-fed serum of humans and animals. In the present study, we have observed that AMS is safe on chronic administration and has a potential antihypertrophic effect. Chronic administration of AMS for 30 days did not cause any significant differences in the body weight, electrocardiogram, food intake, serum biochemical parameters, and histopathology of vital organs. Single-dose pharmacokinetics of AMS suggests that AMS is rapidly metabolized into Allylmethylsulfoxide (AMSO) and Allylmethylsulfone (AMSO2). To evaluate the efficacy of AMS, cardiac hypertrophy was induced by subcutaneous implantation of ALZET® osmotic minipump containing isoproterenol (~5 mg/kg/day), cotreated with AMS (25 and 50 mg/kg/day) and enalapril (10 mg/kg/day) for 2 weeks. AMS and enalapril significantly reduced cardiac hypertrophy as studied by the heart weight to body weight ratio and mRNA expression of fetal genes (ANP and ß-MHC). We have observed that TBARS, a parameter of lipid peroxidation, was reduced and the antioxidant enzymes (glutathione, catalase, and superoxide dismutase) were improved in the AMS and enalapril-cotreated hypertrophic hearts. The extracellular matrix (ECM) components such as matrix metalloproteinases (MMP2 and MMP9) were significantly upregulated in the diseased hearts; however, with the AMS and enalapril, it was preserved. Similarly, caspases 3, 7, and 9 were upregulated in hypertrophic hearts, and with the AMS and enalapril treatment, they were reduced. Further to corroborate this finding with in vitro data, we have checked the nuclear expression of caspase 3/7 in the H9c2 cells treated with isoproterenol and observed that AMS cotreatment reduced it significantly. Histopathological investigation of myocardium suggests AMS and enalapril treatment reduced fibrosis in hypertrophied hearts. Based on our experimental results, we conclude that AMS, an active metabolite of garlic, could reduce isoproterenol-induced cardiac hypertrophy by reducing oxidative stress, apoptosis, and stabilizing ECM components.


Asunto(s)
Compuestos Alílicos/uso terapéutico , Cardiomegalia/tratamiento farmacológico , Ajo/química , Sulfuros/uso terapéutico , Compuestos Alílicos/administración & dosificación , Compuestos Alílicos/metabolismo , Compuestos Alílicos/farmacología , Animales , Antioxidantes/metabolismo , Apoptosis/efectos de los fármacos , Biomarcadores/sangre , Peso Corporal/efectos de los fármacos , Cardiomegalia/sangre , Cardiomegalia/patología , Caspasas/metabolismo , Línea Celular , Matriz Extracelular/efectos de los fármacos , Matriz Extracelular/metabolismo , Fibrosis , Isoproterenol , Peroxidación de Lípido/efectos de los fármacos , Masculino , Metaloproteinasas de la Matriz/metabolismo , Mioblastos/efectos de los fármacos , Mioblastos/metabolismo , Tamaño de los Órganos , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Sulfuros/administración & dosificación , Sulfuros/metabolismo , Sulfuros/farmacología
19.
Ulus Travma Acil Cerrahi Derg ; 26(4): 503-508, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32589234

RESUMEN

BACKGROUND: Inflammatory bowel disease (IBD) is an important health problem. The most important hypotheses for the pathogenesis of this disease are the deterioration of immune responses and loss of tolerance against bacteria in the enteric flora. Although IBD has been widely investigated, its treatment remains difficult. This study aims to investigate the effects of garlic oil (GO) on an experimental colitis model. METHODS: Twenty-eight rats were randomly divided into four equal groups as follows: group 1 (sham), group 2 (control), group 3 (topical treatment) and group 4 (topical and systemic treatment). An acetic acid-induced colitis model was produced in groups 2, 3 and 4 and was administered normal saline, topical GO and topical and systemic GO, respectively. RESULTS: Hydroxyproline levels were lower in the treatment groups than in the control group. TNF-α levels were significantly lower in group 3 than in group 2. Macroscopic scores were significantly lower in group 4 than in group 2. Significant differences were observed between the treatment and control groups according to their epithelial loss. CONCLUSION: GO can reduce colonic damage and inflammation in the acetic acid-induced colitis model, with effects on both local and systemic treatments, but with a more pronounced effect in local treatment.


Asunto(s)
Ácido Acético/efectos adversos , Compuestos Alílicos/uso terapéutico , Colitis/tratamiento farmacológico , Sulfuros/uso terapéutico , Animales , Colitis/inducido químicamente , Modelos Animales de Enfermedad , Ajo , Ratas
20.
Clin Exp Dermatol ; 45(8): 980-985, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32568435

RESUMEN

This review forms part of an annual update series on atopic eczema (AE), where systematic reviews (SRs) are gathered and appraised to provide a summary of key recent research findings. The focus of this article is systemic therapies used in AE, while a review on prevention and topical therapies is provided in Part 1. In total, 17 SRs on various systemic treatments used in AE were first published or indexed in 2018. There is a lack of evidence to support vitamin D supplementation, montelukast and naltrexone in AE treatment. The adverse effects of systemic corticosteroids are the main barrier to their use, and there is also a lack of data to determine the optimal delivery and duration of treatment with them. Of other immunosuppressants, ciclosporin has the most robust evidence of efficacy. Biologic therapies in AE treatment are being increasingly investigated, and to date, the greatest quantity of data and evidence of efficacy relates to dupilumab. The most commonly reported adverse effects are injection-site reactions and conjunctivitis. Other biologics showing some evidence of efficacy include nemolizumab, lebrikizumab and tralokinumab, although further data are needed. There are currently insufficient data on oral small molecules, including Janus kinase inhibitors, in the treatment of AE. A Cochrane review on probiotics showed no significant benefit, and SRs and meta-analyses on complementary and alternative medicines, including probiotics, in paediatric AE demonstrated significant heterogeneity, thereby limiting their interpretation. This summary of recent SRs provides up-to-date evidence for clinicians on systemic therapies in AE.


Asunto(s)
Dermatitis Atópica/tratamiento farmacológico , Eccema/tratamiento farmacológico , Eccema/patología , Acetatos/administración & dosificación , Acetatos/efectos adversos , Acetatos/uso terapéutico , Corticoesteroides/efectos adversos , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales Humanizados/uso terapéutico , Terapia Biológica/efectos adversos , Terapia Biológica/métodos , Terapia Biológica/estadística & datos numéricos , Niño , Terapias Complementarias/efectos adversos , Terapias Complementarias/métodos , Terapias Complementarias/estadística & datos numéricos , Ciclopropanos/administración & dosificación , Ciclopropanos/efectos adversos , Ciclopropanos/uso terapéutico , Ciclosporina/administración & dosificación , Ciclosporina/uso terapéutico , Inductores del Citocromo P-450 CYP1A2/administración & dosificación , Inductores del Citocromo P-450 CYP1A2/efectos adversos , Inductores del Citocromo P-450 CYP1A2/uso terapéutico , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/prevención & control , Eccema/diagnóstico , Eccema/prevención & control , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Inhibidores de las Cinasas Janus/uso terapéutico , Naltrexona/administración & dosificación , Naltrexona/efectos adversos , Naltrexona/uso terapéutico , Antagonistas de Narcóticos/administración & dosificación , Antagonistas de Narcóticos/efectos adversos , Antagonistas de Narcóticos/uso terapéutico , Omalizumab/efectos adversos , Omalizumab/uso terapéutico , Efecto Placebo , Probióticos/efectos adversos , Probióticos/uso terapéutico , Quinolinas/administración & dosificación , Quinolinas/efectos adversos , Quinolinas/uso terapéutico , Sulfuros/administración & dosificación , Sulfuros/efectos adversos , Sulfuros/uso terapéutico , Ustekinumab/efectos adversos , Ustekinumab/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA